Current Evidence on Therapeutic Approaches to BCBM: HER2-Negative Disease

Download this slideset for an expert-curated overview of the latest clinical data informing optimal management of HER2-negative breast cancer brain metastases, including a look at new strategies on the horizon.
Ruth O'Regan, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.04 MB
Released: December 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Puma Biotechnology, Inc.

Related Content

Slides from Sara Tolaney, MD, MPH, on adjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Sara Tolaney, MD, MPH Released: June 16, 2021

Slides from Joyce O’Shaughnessy, MD, on measures of treatment benefit for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: June 15, 2021

Slides from Sara Hurvitz, MD, FACP, on neoadjuvant therapy with CDK4/6 inhibitors for HR+/HER2- early breast cancer from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Released: June 15, 2021

MONALEESA-3 updated survival analysis with ribociclib + fulvestrant in advanced breast cancer, from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue